ILNS News 0.0086 07/24/2014 05:21:05 Intellect Neuroscien (I

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Intellect Neuroscien (ILNS) 0.0086 $ILNS

Intellect Neurosciences, Inc. Announces Positive Top Line Data Showing Proof of Concept in a Preclinical Alzheimer's Model for Its TauC3 Monoclonal Antibody Indicating its Potential to be Disease Modifying
GlobeNewswire - Thu Jan 16, 2:19AM CST
via PRWEB - Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and diagnostic agents for the treatment of Alzheimer's and other neurological diseases, today announced it obtained proof of concept in a preclinical Alzheimer's model for its TauC3 monoclonal antibody indicating its potential to be disease modifying. The study was conducted in collaboration with University of California, Irvine's Dr. Frank LaFerla, Chancellor's Professor and Chair, Neurobiology and Behavior School of Biological Sciences, Director, Institute for Memory Impairments and Neurological Disorders as well as Dr. Kim Green and his team. The data showed that the TauC3 antibody effectively engaged the target and reduced certain phosphorylated pathological forms of Tau indicating that the treatment with the peripherally administered antibody had an effect in the brain and is able to be disease modifying. The investigators aim to publish the full data in a peer-reviewed scientific journal.

OTC Daily Alert Stock Watch - Intellect Neurosciences, Inc. (OTCQB:ILNS)
WorldStockWire - Tue Aug 13, 6:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Intellect Neurosciences Retains Chain Pharmaceuticals LLC
GlobeNewswire - Tue Jul 30, 10:30AM CDT
Intellect Neurosciences, Inc. (OTCBB:ILNS) announced today it has retained Chain Pharmaceuticals LLC as a consultant to assist the company in managing its patent estate and external collaborations and pursuing strategic alternatives for the company, which may include partnerships, strategic business model alternatives, a sale or other transaction.

Intellect Neurosciences, Inc. Issues Letter to Shareholders
GlobeNewswire - Thu Jun 20, 8:25AM CDT
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of treatments for the prevention and treatment of neurodegenerative diseases, issued the following Letter to Shareholders from Elliot Maza, a member of the Board of Directors of the company.

NY biotech financier gets prison for stock scheme
By LARRY NEUMEISTER - AP - Thu May 02, 7:35PM CDT
NEW YORK (AP) — A federal judge displayed anger as she handed down a four-year prison sentence Thursday to a biotechnology financier who was once among the nation's wealthiest people.

Intellect Neurosciences Issues Letter to Shareholders
GlobeNewswire - Fri Mar 29, 8:35AM CDT
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of treatments for the prevention and treatment of neurodegenerative diseases, issued the following Letter to Shareholders from Dr. Daniel Chain, Chairman and CEO.

Intellect Neurosciences to Present at Bio-Europe Spring Conference in Barcelona
GlobeNewswire - Thu Feb 28, 8:35AM CST
Intellect Neurosciences, Inc. (OTCBB:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, will present at the Bio-Europe Spring Conference March 11-13, 2012 at the Centre Convencions Internacional in Barcelona, Spain.

Market Maker Surveillance Report. DVAX, FCX, PSSI, CIM, S, ILNS, Highest Net Sell Volume and Negative Price Friction For Tuesday, February 19th 2013
M2 - Wed Feb 20, 2:23AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3840 companies with "abnormal" market making, 3574 companies with positive Friction Factors and 2220 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Tuesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Dynavax Technologies Corp (NASDAQ VAX), Freeport-McMoRan Copper & Gold Inc (NYSE:FCX), PSS World Medical Inc (NASDAQ SSI), Chimera Investment Corp (NYSE:CIM), Sprint Nextel Corp (NYSE:S), INTELLECT NEUROSCIENCES INC (OTC:ILNS). To access Friction Factor, Naked

Intellect Neurosciences Initiates in vivo Proof of Concept Studies in a Preclinical Alzheimer's Model for Its TauC3 Monoclonal Antibody
GlobeNewswire - Thu Feb 07, 8:35AM CST
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced it has initiated in vivo proof of concept studies for its monoclonal antibody, TauC3, in a preclinical model of Alzheimer's disease. The studies are being conducted in collaboration with University of California, Irvine's Dr. Frank LaFerla, Chancellor's Professor and Chair, Neurobiology and Behavior School of Biological Sciences, Director, Institute for Memory Impairments and Neurological Disorders as well as Dr. Kim Green and his team.

Novel Alzheimer's Therapeutics Developer Says Investors Should Remain Undeterred Despite Disappointing Results From Major Phase 3 Trials
Marketwire - Wed Jan 30, 7:08AM CST
During his distinguished career, Dr. Daniel G. Chain, Ph.D. discovered various novel therapeutics to treat Alzheimer's disease which were licensed to multiple Big Pharma giants.

Intellect Neurosciences CEO Daniel Chain Provides Conference Highlights of Alzheimer's Drug Development Summit in Neurotech Insights Magazine
GlobeNewswire - Wed Jan 02, 8:35AM CST
Intellect Neurosciences, Inc. (OTCBB:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, provided conference highlights from the December 11-12 Alzheimer's Drug Development Summit in Neurotech Insights magazine. Dr. Chain was a Distinguished Speaker at the conference.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 387

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 544

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 109

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 411

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 174

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Roche Unveils High-Sensitivity Troponin T Test Increasing Diagnosis Precision

Updated Category News Views 350

The Unveiling of Roche's Sixth-Generation Troponin T Test Roche has recently been granted a CE Mark for its innovative sixth-generation Troponin T test, which promises to deliver a new level of accuracy that is critical for diagnosing heart attacks. This novel testing solution is designed to enhance sensitivity and precision, allowing for quicker and more reliable...

Continue Reading
Maximize Your Earnings with Keurig Dr Pepper Stock Strategy

Updated Category News Views 133

Understanding Keurig Dr Pepper's Earnings Potential Keurig Dr Pepper Inc. (NASDAQ: KDP) is preparing to share its third quarter earnings results shortly. Investors eagerly await the disclosures, which are expected to highlight positive financial trends and growth. Analysts predict that the company will report earnings per share of 54 cents, an increase from 51 cents in...

Continue Reading
Uwharrie Capital Corp Celebrates Year-End Financial Growth

Updated Category News Views 113

Uwharrie Capital Corp Reports Strong Year-End Results Uwharrie Capital Corp and its subsidiary, Uwharrie Bank, have recently unveiled impressive financial results that reflect their continued strength and stability in the banking sector. The company reported consolidated total assets of $1.13 billion at the end of the reporting period, demonstrating a noticeable increase...

Continue Reading
Enhancing California's Tourism Appeal with Interactive Design

Updated Category News Views 148

Revolutionizing Tourism Through Interactive Web Design In today's fast-paced digital world, engaging younger travellers has become crucial for tourism boards in California. Digital Silk, an award-winning agency renowned for its expertise in digital marketing and web design, is leading the charge to inspire Generation Z and millennials by advocating for the adoption of...

Continue Reading
FOX News Digital Dominates October with Record-Breaking View Counts

Updated Category News Views 174

FOX News Digital Achieves Historic Success in October Leading YouTube with 377 Million Video Views During the month of October, FOX News Digital achieved outstanding milestones, topping the charts in multiplatform engagement. With a staggering 3.7 billion multiplatform minutes and 1.8 billion views, the platform outshined its competitors, establishing its dominance in the...

Continue Reading